Administration of Anti–SARS-CoV-2 Monoclonal Antibodies After US Food and Drug Administration Deauthorization
Timothy S. Anderson, Ashley L. O’Donoghue, Oren Mechanic, Tenzin Dechen, Jennifer P. Stevens
Abstract
This cross-sectional study uses time-series data to evaluate the administration of bamlanivimab-etesevimab and casirivimab-imdevimab monoclonal antibody treatments for SARS-CoV-2 infection after the US Food and Drug Administration deauthorized their use in early 2022.
Topics & Concepts
Food and drug administrationMonoclonal antibodyAdministration (probate law)VirologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)Medicine2019-20 coronavirus outbreakDrugDrug administrationAntibodyPharmacologyImmunologyInternal medicinePolitical scienceInfectious disease (medical specialty)OutbreakDiseaseLawSARS-CoV-2 and COVID-19 ResearchBiosimilars and Bioanalytical MethodsMonoclonal and Polyclonal Antibodies Research